[{"address1": "3891 Ranchero Drive", "address2": "Suite 150", "city": "Ann Arbor", "state": "MI", "zip": "48108", "country": "United States", "phone": "734 887 3903", "website": "https://www.esperion.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.", "fullTimeEmployees": 304, "companyOfficers": [{"maxAge": 1, "name": "Mr. Benjamin  Halladay M.B.A.", "age": 38, "title": "Chief Financial Officer", "yearBorn": 1986, "fiscalYear": 2024, "totalPay": 713958, "exercisedValue": 0, "unexercisedValue": 5625}, {"maxAge": 1, "name": "Mr. Benjamin O. Looker J.D.", "age": 42, "title": "General Counsel & Corporate Secretary", "yearBorn": 1982, "fiscalYear": 2024, "totalPay": 696350, "exercisedValue": 0, "unexercisedValue": 4219}, {"maxAge": 1, "name": "Tiffany  Aldrich M.B.A.", "title": "Associate Director of Corporate Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Betty Jean Swartz", "title": "Chief Business Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Glenn P. Brame", "age": 66, "title": "Chief Technical Operations Officer", "yearBorn": 1958, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Stephen  Pinkosky", "title": "Vice President of Drug Discovery of Early Pre-Clinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1759276800, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.455, "open": 2.47, "dayLow": 2.44, "dayHigh": 2.59, "regularMarketPreviousClose": 2.455, "regularMarketOpen": 2.47, "regularMarketDayLow": 2.44, "regularMarketDayHigh": 2.59, "payoutRatio": 0.0, "beta": 0.961, "forwardPE": 12.65, "volume": 7447118, "regularMarketVolume": 7447118, "averageVolume": 6778598, "averageVolume10days": 10652930, "averageDailyVolume10Day": 10652930, "bid": 2.5, "ask": 2.56, "bidSize": 19, "askSize": 45, "marketCap": 586005760, "fiftyTwoWeekLow": 0.69, "fiftyTwoWeekHigh": 3.94, "allTimeHigh": 120.96, "allTimeLow": 0.69, "priceToSalesTrailing12Months": 2.1855693, "fiftyDayAverage": 2.3792, "twoHundredDayAverage": 1.6638, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1022222720, "profitMargins": -0.38796002, "floatShares": 200003794, "sharesOutstanding": 231622825, "sharesShort": 27694381, "sharesShortPriorMonth": 22348965, "sharesShortPreviousMonthDate": 1756425600, "dateShortInterest": 1759190400, "sharesPercentSharesOut": 0.1374, "heldPercentInsiders": 0.00453, "heldPercentInstitutions": 0.43953, "shortRatio": 3.93, "shortPercentOfFloat": 0.138, "impliedSharesOutstanding": 203580328, "bookValue": -2.166, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -104022000, "trailingEps": -0.54, "forwardEps": 0.2, "enterpriseToRevenue": 3.812, "enterpriseToEbitda": -28.925, "52WeekChange": 0.21052635, "SandP52WeekChange": 0.118204355, "quoteType": "EQUITY", "currentPrice": 2.53, "targetHighPrice": 16.0, "targetLowPrice": 1.6, "targetMeanPrice": 6.08571, "targetMedianPrice": 4.0, "recommendationMean": 2.25, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 86061000, "totalCashPerShare": 0.427, "ebitda": -35341000, "totalDebt": 598177984, "quickRatio": 0.649, "currentRatio": 1.147, "totalRevenue": 268124992, "revenuePerShare": 1.367, "returnOnAssets": -0.06335, "grossProfits": 123958000, "freeCashflow": -120302496, "operatingCashflow": -124327000, "revenueGrowth": 0.116, "grossMargins": 0.46231, "ebitdaMargins": -0.13181, "operatingMargins": 0.08612, "financialCurrency": "USD", "symbol": "ESPR", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1760140278, "regularMarketTime": 1760126400, "exchange": "NGM", "messageBoardId": "finmb_28236", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "shortName": "Esperion Therapeutics, Inc.", "regularMarketChangePercent": 3.05499, "regularMarketPrice": 2.53, "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 6778598, "fiftyTwoWeekLowChange": 1.8399999, "fiftyTwoWeekLowChangePercent": 2.6666665, "fiftyTwoWeekRange": "0.69 - 3.94", "fiftyTwoWeekHighChange": -1.4100001, "fiftyTwoWeekHighChangePercent": -0.35786805, "fiftyTwoWeekChangePercent": 21.052635, "earningsTimestamp": 1754397000, "earningsTimestampStart": 1762259400, "earningsTimestampEnd": 1762259400, "earningsCallTimestampStart": 1754395200, "earningsCallTimestampEnd": 1754395200, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -0.54, "epsForward": 0.2, "epsCurrentYear": -0.01667, "priceEpsCurrentYear": -151.76965, "fiftyDayAverageChange": 0.15079999, "fiftyDayAverageChangePercent": 0.06338265, "twoHundredDayAverageChange": 0.8662, "twoHundredDayAverageChangePercent": 0.52061546, "priceToBook": -1.1680517, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.3 - Buy", "cryptoTradeable": false, "longName": "Esperion Therapeutics, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1372253400000, "regularMarketChange": 0.075, "regularMarketDayRange": "2.44 - 2.59", "postMarketChangePercent": -1.57708, "postMarketPrice": 2.4901, "postMarketChange": -0.0399001, "displayName": "Esperion Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-10-11"}]